Omeros (FRA:3O8) Change In Other Working Capital : €0.32 Mil (TTM As of Dec. 2023)

View and export this data going back to 2009. Start your Free Trial

What is Omeros Change In Other Working Capital?

Omeros's Change In Other Working Capital for the quarter that ended in Dec. 2023 was €-27.42 Mil. It means Omeros's Other Working Capital declined by €27.42 Mil from Sep. 2023 to Dec. 2023 .

Omeros's Change In Other Working Capital for the fiscal year that ended in Dec. 2023 was €0.00 Mil. It means Omeros's Other Working Capital increased by €0.00 Mil from Dec. 2022 to Dec. 2023 .

Omeros Change In Other Working Capital Historical Data

The historical data trend for Omeros's Change In Other Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Omeros Change In Other Working Capital Chart

Omeros Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Other Working Capital

Get a 7-Day Free Trial

0.95

0.17

Omeros Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Other Working Capital	Get a 7-Day Free Trial															-44.89	-	18.38	9.36	-27.42

Omeros Change In Other Working Capital Calculation

Change In Other Working Capital is any increase or decrease between periods of other working capital that are not otherwise classified.

Change In Other Working Capital for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.32 Mil.

Omeros Change In Other Working Capital Related Terms

Thank you for viewing the detailed overview of Omeros's Change In Other Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Omeros (FRA:3O8) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Omeros Corp (FRA:3O8) » Definitions » Change In Other Working Capital

Comparable Companies

Traded in Other Exchanges

OMER:USA 3O8:Germany

Address

201 Elliott Avenue West, Seattle, WA, USA, 98119

Website

https://www.omeros.com

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Omeros (FRA:3O8) Headlines

No Headlines